adssx
#283
Interesting. I cannot find explicit sources saying that VNA-318 is a urolithin derivative. But Vandria was spun out of Amazentis SA (developers of Mitopure) and they filed this patent: WO2024023585A2 - Urolithin derivatives and therapeutic uses - Google Patents
1 Like
Karel1
#284
If I am correct this patent application is extremely broad and could cover thousands of substances and could therefore potentially prohibit competition to do any research on them.
This way vulture capitalist could dominate the marketplace in a way not beneficial to mankindā¦
Most patent applications start out as broadly as possible, but then get narrowed over time through the patent approval process, challenges by competitors, etc. so I wouldnāt worry about this right now.
3 Likes
adssx
#286
Also, unfortunately, without that kind of patent thereās 0 financial incentive to do research on compounds such as urolithin A. So Iām glad they found a way to make money with this compound. Otherwise we just have small low-quality trials funded by academia (often in Iran, India or China) as we see with other supplementsā¦
3 Likes
Maxi
#287
I took Urolithin for 9 months to beat ME/CFS based on the autophagy expectations. One of the many trials which had no effect whatsoever. Now I started Rapa.
3 Likes
Jay
#288
francesss7ca, In what ways do you want to see if it will help your eyes? Do you have any research to suggest it may have some eye health benefits, especially at only 1 mg per week?
adssx
#289
Urolithin A Provides Cardioprotection and Mitochondrial Quality Enhancement in Rodents and Improves Human Cardiovascular Biomarkers 2025
Paper by the Amazentis/Mitopure team:
Urolithin A enhances heart mitochondrial quality in aging and heart failure models
Cardiac function decline in these models is reduced by Urolithin A
In humans, Urolithin A lowers plasma ceramides associated with heart disease risk
Urolithin A is a promising nutritional approach to support heart health as we age
4 Likes
For the record, the reduction in ceramides is not new data: they are referring back to their 2022 trial in JAMA Network Open.
2 Likes
adssx
#291
Urolithin A alleviates NLRP3 inflammasome activation and pyroptosis by promoting microglial mitophagy following spinal cord injury 2025
UrolithinA attenuates NLRP3 inflammasome activation and pyroptosis in microglia.
UrolithinA alleviates NLRP3 Inflammasome Activation and Pyroptosis by Promoting Microglial Mitophagy.
UrolithinA alleviates NLRP3 inflammasome activation and pyroptosis by promoting the activation of autophagy in spinal cord injuried mice.
1 Like
Every now and then I look at the bottle of Double Wood Urolithin A I bought, but havenāt yet used, and wonder about it. If youāve been taking it, do you think itās the real thing?
Doublewood is a good manufacturer. The supplement is probably the real deal. I just wonder if it moves the needle for longevity.
On my long list of things to test I want to see if a high dose of UA moves the needle on glucose/WBC etc. If it inhibits mTOR then it should have the same effects as Rapamycin.
My assumption at the moment is that it does the same as Rapamycin, but at a much lower intensity.
1 Like
Please let us know the results of your experience with it!
I will do, but I have a long list of things to try. It has a half life of under a day which in some ways makes it better than rapamycin as the period of vulnerability to infection is shorter.
1 Like
adssx
#297
1 Like
adssx
#298
Urolithin A alleviates schizophrenic-like behaviors and cognitive impairment in rats through modulation of neuroinflammation, neurogenesis, and synaptic plasticity 2025
The findings suggest that changes in cognitive function linked to schizophrenia are driven by the interaction among neuroinflammation, neurogenesis, and synaptic plasticity and that UA has the potential to reverse these processes. These observations provide evidence for future clinical trials of UA as a dietary supplement for preventing schizophrenia.
4 Likes
Great read, I hope there will some human studies some time soon
